IL155250A0 - Methods of modulating apoptosis by administration of relaxin agonists or antagonists - Google Patents

Methods of modulating apoptosis by administration of relaxin agonists or antagonists

Info

Publication number
IL155250A0
IL155250A0 IL15525001A IL15525001A IL155250A0 IL 155250 A0 IL155250 A0 IL 155250A0 IL 15525001 A IL15525001 A IL 15525001A IL 15525001 A IL15525001 A IL 15525001A IL 155250 A0 IL155250 A0 IL 155250A0
Authority
IL
Israel
Prior art keywords
antagonists
administration
methods
modulating apoptosis
relaxin agonists
Prior art date
Application number
IL15525001A
Other languages
English (en)
Original Assignee
Molecular Medicine Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Medicine Res Inst filed Critical Molecular Medicine Res Inst
Publication of IL155250A0 publication Critical patent/IL155250A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
IL15525001A 2000-10-04 2001-10-04 Methods of modulating apoptosis by administration of relaxin agonists or antagonists IL155250A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23823200P 2000-10-04 2000-10-04
US24203700P 2000-10-20 2000-10-20
US24199100P 2000-10-20 2000-10-20
PCT/US2001/042484 WO2002028418A1 (en) 2000-10-04 2001-10-04 Methods of modulating apoptosis by administration of relaxin agonists or antagonists

Publications (1)

Publication Number Publication Date
IL155250A0 true IL155250A0 (en) 2003-11-23

Family

ID=27399064

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15525001A IL155250A0 (en) 2000-10-04 2001-10-04 Methods of modulating apoptosis by administration of relaxin agonists or antagonists

Country Status (7)

Country Link
EP (1) EP1326627A4 (ja)
JP (3) JP2004510743A (ja)
AU (2) AU2002211855B2 (ja)
CA (2) CA2425712C (ja)
IL (1) IL155250A0 (ja)
NZ (1) NZ525389A (ja)
WO (1) WO2002028418A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006205A1 (en) * 2001-04-03 2004-01-08 Li Li Therapeutic polypeptides, nucleic acids encoding same, and methods of use
PL2510942T3 (pl) 2005-04-07 2016-02-29 Cardiorentis Ag Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca
AU2007236516B2 (en) * 2006-04-11 2013-01-17 Armour Therapeutics, Inc. Modified H2 relaxin for tumor suppression
KR20110099762A (ko) * 2008-12-26 2011-09-08 고쿠리츠다이가쿠호우진 도쿄다이가쿠 항ｌｇｒ７항체를 사용하는 암의 진단 및 치료
KR20150108903A (ko) * 2013-01-25 2015-09-30 카디오렌티스 엘티디. 심혈관 징후의 치료 방법에 사용하기 위한 나트륨이뇨 펩티드, 이뇨 펩티드 또는 혈관확장성 펩티드
CN113147632B (zh) * 2021-05-17 2023-03-07 中国第一汽车股份有限公司 一种车辆控制方法、装置、车辆及存储介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH661662A5 (en) * 1984-04-16 1987-08-14 Georg L Prof Dr Floersheim Product for the treatment of the skin and of the connective tissue
WO1994029452A2 (en) * 1993-06-09 1994-12-22 Ribozyme Pharmaceuticals, Inc. Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease
AU7687194A (en) * 1993-09-14 1995-04-03 Mallinckrodt Medical, Inc. Therapeutic treatment for inhibiting blood vessel blockage using a polypeptide
US5811395A (en) * 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
WO1999040929A1 (en) * 1998-02-12 1999-08-19 The General Hospital Corporation Methods to potentiate cancer therapies

Also Published As

Publication number Publication date
CA2967607A1 (en) 2002-04-11
EP1326627A4 (en) 2004-06-16
AU2002211855B2 (en) 2007-06-07
JP2012184273A (ja) 2012-09-27
CA2425712C (en) 2017-06-06
WO2002028418B1 (en) 2002-07-18
JP2008297313A (ja) 2008-12-11
JP2004510743A (ja) 2004-04-08
AU1185502A (en) 2002-04-15
EP1326627A1 (en) 2003-07-16
WO2002028418A1 (en) 2002-04-11
CA2425712A1 (en) 2002-04-11
NZ525389A (en) 2009-04-30

Similar Documents

Publication Publication Date Title
EE200300246A (et) EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks
IS6388A (is) EP4 viðtaka valvís gerandefni í meðhöndluninni á beingisnun
CY2013011I1 (el) Μεθοδος χορηγησης διφωσφονικων
CY2014003I2 (el) Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
NO20013183L (no) Azabicykloalkaner som CCR5-modulatorer
ZA200204826B (en) Preparation of concrete accellerator.
PL357780A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatement of pain
IL151093A0 (en) Derivatives of quinoline as alpha-2 antagonists
PL350347A1 (en) Method of obtaining non-steroidic modulators of the glucosteroid receptor
NO20023770L (no) Indol-3-ylderivater
ZA200305803B (en) Prevention of diabetes by administration of GnRH antagonists.
IL155250A0 (en) Methods of modulating apoptosis by administration of relaxin agonists or antagonists
HK1045684A1 (en) Biphenyl derivatives as antagonists of the neurokinine-1 receptor.
ZA200109206B (en) Preparation of substituted piperidin-4-ones.
ZA200303113B (en) Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them.
MXPA03005405A (es) Formulacion farmaceutica que contiene tienopirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina.
HK1045260A1 (en) Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use.
AU2002216245A1 (en) Methods of modulating toll-related receptor (trr) signaling
DE60023020T2 (de) Positive modulatoren von nicotinrezeptor-agonisten
AU2001264900A1 (en) Pharmaceutical use of fibulin-1
ITRM20020357A1 (it) Composizione liquida per la somministrazione orale di lorazepam.
GB0021927D0 (en) Use of pharmaceutical combination
GB0022644D0 (en) Antitumoral derivatives of ET-743
TW376154U (en) Laser level of multi-angle directions
GB0010124D0 (en) Administration of beneficial substances